KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Accounts Payables: 2017-2025

Historic Accounts Payables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $731.8 million.

  • Amneal Pharmaceuticals' Accounts Payables rose 9.05% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year increase of 9.05%. This contributed to the annual value of $735.5 million for FY2024, which is 37.55% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Accounts Payables of $731.8 million as of Q3 2025, which was up 9.75% from $666.8 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Accounts Payables registered a high of $735.5 million during Q4 2024, and its lowest value of $467.4 million during Q1 2023.
  • Its 3-year average for Accounts Payables is $607.6 million, with a median of $619.2 million in 2024.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Accounts Payables declined by 14.14% in 2021, and later soared by 37.55% in 2024.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Accounts Payables stood at $525.3 million in 2021, then rose by 2.45% to $538.2 million in 2022, then declined by 0.66% to $534.7 million in 2023, then soared by 37.55% to $735.5 million in 2024, then rose by 9.05% to $731.8 million in 2025.
  • Its last three reported values are $731.8 million in Q3 2025, $666.8 million for Q2 2025, and $628.6 million during Q1 2025.